Fig 4A and 4C show that the chimeric gBHER2, and gHHER2 reacted with soluble HER2, whereas the wt-gB and wt-gH did not. This result shows that the binding of gBHER2, or gHHER2 to HER2 occurs in the absence of the other glycoproteins. For the infection assay, we infected J-HER2 or SK-OV-3 cells in the presence of trastuzumab. A wt HSV was not included as it does not infect J-HER2 cells (see Fig 2A and references [44] and [45]). Trastuzumab blocked entry of R-909 and R-LM113, but not of R-LM5 (Fig 4E), indicating that R-909 uses HER2 as a portal of entry. Here, ERBB2 is linked to infection.